ArticleEndocrine connections2025
Association of increased serum I-309 with renal function impairment and diabetic kidney disease in type 2 diabetes mellitus.
Article in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study was to determine serum I-309 levels in type 2 diabetes mellitus (T2DM) patients, as well as the association with clinical/laboratory phenotypes and disease complications. Methods: A total of 155 T2DM patients and 30 healthy controls (HC) were enrolled. The concentrations of serum I-309, interleukin-4 (IL-4), IL-6, IL-10, IL-12, IL-17, IL-23, tumor necrosis factor-α (TNF-α), and interferon (IFN)-γ were measured. The relationships between I-309 and various clinical and laboratory variables were analyzed. Results: The serum concentrations of I-309 were significantly higher in T2DM patients than in HC (P < 0.001). The serum I-309 levels were significantly elevated in T2DM patients with diabetic kidney disease (DKD), hypertension, coronary artery disease, peripheral neuropathy, peripheral artery disease, and diabetic ketosis (all P < 0.05), but reduced in drinkers (P = 0.018). The Spearman analysis showed that serum I-309 correlated positively with age, disease duration, CKD stages, urea, creatinine, urinary albumin-to-creatinine ratio, C-reactive protein, red blood cell distribution width, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, IL-6, IL-12, and IFN-γ, but negatively with estimated glomerular filtration rate (eGFR), fasting blood glucose, total bilirubin, albumin, lymphocyte count, red blood cell count, and hemoglobin. The multiple linear regression analysis indicated that serum I-309 was independently correlated only with eGFR and IFN-γ. The multivariate logistic regression analysis demonstrated that serum I-30 and IL-17A remained independently associated with DKD. Conclusion: Serum I-309 is markedly elevated in T2DM patients and is associated with increased DKD risk, suggesting its potential role as both a promising biomarker and a pathogenic mediator in the progression of T2DM, particularly DKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.